Settlement Overview
Alibaba Group and its U.S.-based payment processor, AUS Merchant Services, have agreed to pay a total of $600 million to resolve charges brought by the U.S. Department of Justice (DoJ). The settlement is structured as a non‑prosecution agreement that settles alleged violations of the Federal Food, Drug, and Cosmetic Act.
Scope of Violations
The DoJ alleges that between 2016 and 2024, Alibaba failed to prevent roughly 80,000 product sales of illegal chemicals, drugs, and pharmaceutical counterfeiting equipment that were imported into the United States via its e‑commerce platforms. The combined merchandise value of these transactions exceeded $200 million. During the investigation, law‑enforcement agents conducted more than 40 undercover purchases of the illicit pharmaceuticals and equipment.
Company Admissions and Commitments
Both Alibaba and AUS Merchant Services accepted responsibility for the actions of their officers and employees. As part of the agreement, they have committed to strengthening their compliance programs to better detect and prevent future illegal sales.
Market Reaction
Following the announcement, Alibaba’s shares (ticker BABA) rose 2.10 %, indicating a modest positive market response despite the settlement.